1---2name: healthcare-marketing-compliance3description: Core Mission4metadata:5 source: https://skillmd.com/skills/travisleeeeee/healthcare-marketing-compliance6---7## Core Mission89### Medical Advertising Compliance1011- Master China's core medical advertising regulatory framework:12 - **Advertising Law of the PRC (Guanggao Fa)**: Article 16 (restrictions on medical, pharmaceutical, and medical device advertising), Article 17 (no publishing without review), Article 18 (health supplement advertising restrictions), Article 46 (medical advertising review system)13 - **Medical Advertisement Management Measures (Yiliao Guanggao Guanli Banfa)**: Content standards, review procedures, publication rules, violation penalties14 - **Internet Advertising Management Measures (Hulianwang Guanggao Guanli Banfa)**: Identifiability requirements for internet medical ads, popup ad restrictions, programmatic advertising liability15- Prohibited terms and expressions in medical advertising:16 - **Absolute claims**: "Best efficacy," "complete cure," "100% effective," "never relapse," "guaranteed recovery"17 - **Guarantee promises**: "Refund if ineffective," "guaranteed cure," "results in one session," "contractual treatment"18 - **Inducement language**: "Free treatment," "limited-time offer," "condition will worsen without treatment" — language creating false urgency19 - **Improper endorsements**: Patient recommendations/testimonials of efficacy, using medical research institutions, academic organizations, or healthcare facilities or their staff for endorsement20 - **Efficacy comparisons**: Comparing effectiveness with other drugs or medical institutions21- Advertising review process key points:22 - Medical advertisements must be reviewed by provincial health administrative departments and obtain a Medical Advertisement Review Certificate (Yiliao Guanggao Shencha Zhengming)23 - Drug advertisements must obtain a drug advertisement approval number, valid for one year24 - Medical device advertisements must obtain a medical device advertisement approval number25 - Ad content must not exceed the approved scope; content modifications require re-approval26 - Establish an internal three-tier review mechanism: Legal initial review -> Compliance secondary review -> Final approval and release2728### Pharmaceutical Marketing Standards2930- Core differences between prescription and OTC drug marketing:31 - **Prescription drugs (Rx)**: Strictly prohibited from advertising in mass media (TV, radio, newspapers, internet) — may only be published in medical and pharmaceutical professional journals jointly designated by the health administration and drug regulatory departments of the State Council32 - **OTC drugs**: May advertise in mass media but must include advisory statements such as "Please use according to the drug package insert or under pharmacist guidance"33 - **Prescription drug online marketing**: Must not use popular science articles, patient stories, or other formats to covertly promote prescription drugs; search engine paid rankings must not include prescription drug brand names34- Drug label compliance:35 - Indications, dosage, and adverse reactions in marketing materials must match the NMPA-approved package insert exactly36 - Must not expand indications beyond the approved scope (off-label promotion is a violation)37 - Drug name usage: Distinguish between generic name and trade name usage contexts38- NMPA (National Medical Products Administration / Guojia Yaopin Jiandu Guanli Ju) regulations:39 - Drug registration classification and corresponding marketing restrictions40 - Post-market adverse reaction monitoring and information disclosure obligations41 - Generic drug bioequivalence certification promotion rules — may promote passing bioequivalence studies, but must not claim "completely equivalent to the originator drug"42 - Online drug sales management: Requirements of the Online Drug Sales Supervision and Management Measures (Yaopin Wangluo Xiaoshou Jiandu Guanli Banfa) for online drug display, sales, and delivery4344### Medical Device Promotion4546- Medical device classification and regulatory tiers:47 - **Class I**: Low risk (e.g., surgical knives, gauze) — filing management, fewest marketing restrictions48 - **Class II**: Moderate risk (e.g., thermometers, blood pressure monitors, hearing aids) — registration certificate required for sales and promotion49 - **Class III**: High risk (e.g., cardiac stents, artificial joints, CT equipment) — strictest regulation, advertising requires review and approval50- Registration certificate and promotion compliance:51 - Product name, model, and intended use in promotional materials must exactly match the registration certificate/filing information52 - Must not promote unregistered products (including "coming soon," "pre-order," or similar formats)53 - Imported devices must display the Import Medical Device Registration Certificate54- Clinical data citation standards:55 - Clinical trial data citations must note the source (journal name, publication date, sample size)56 - Must not selectively cite favorable data while concealing unfavorable results57 - When citing overseas clinical data, must note whether the study population included Chinese subjects58 - Real-world study (RWS) data citations must note the study type and must not be equated with registration clinical trial conclusions5960### Internet Healthcare Compliance6162- Core regulatory framework:63 - **Internet Diagnosis and Treatment Management Measures (Trial) (Hulianwang Zhengliao Guanli Banfa Shixing)**: Defines internet diagnosis and treatment, entry conditions, and regulatory requirements64 - **Internet Hospital Management Measures (Trial)**: Setup approval and practice management for internet hospitals65 - **Remote Medical Service Management Standards (Trial)**: Applicable scenarios and operational standards for telemedicine66- Internet diagnosis and treatment compliance red lines:67 - Must not provide internet diagnosis and treatment for first-visit patients — first visits must be in-person68 - Internet diagnosis and treatment is limited to follow-up visits for common diseases and chronic conditions69 - Physicians must be registered and licensed at their affiliated medical institution70 - Electronic prescriptions must be reviewed by a pharmacist before dispensing71 - Online consultation records must be included in electronic medical record management72- Major internet healthcare platform compliance points:73 - **Haodf (Good Doctor Online)**: Physician onboarding qualification review, patient review management, text/video consultation standards74 - **DXY (Dingxiang Yisheng / DingXiang Doctor)**: Professional review mechanism for health education content, physician certification system, separation of commercial partnerships and editorial independence75 - **WeDoctor (Weiyi)**: Internet hospital licenses, online prescription circulation, medical insurance integration compliance76 - **JD Health / Alibaba Health**: Online drug sales qualifications, prescription drug review processes, logistics and delivery compliance77- Special requirements for internet healthcare marketing:78 - Platform promotion must not exaggerate online diagnosis and treatment effectiveness79 - Must not use "free consultation" as a lure to collect personal health information for commercial purposes80 - Boundary between online consultation and diagnosis: Health consultation is not a medical act, but must not disguise diagnosis as consultation8182### Health Content Marketing8384- Health education content creation compliance:85 - Content must be based on evidence-based medicine; cited literature must note sources86 - Boundary between health education and advertising: Must not embed product promotion in health education articles87 - Common compliance risks in health content: Over-interpreting study conclusions, fear-mongering headlines ("You'll regret not reading this"), treating individual cases as universal rules88 - Traditional Chinese medicine wellness content requires caution: Must note "individual results vary; consult a professional physician" — must not claim to replace conventional medical treatment89- Physician personal brand compliance:90 - Physicians must appear under their real identity, displaying their Medical Practitioner Qualification Certificate and Practice Certificate91 - Relationship declaration between the physician's personal account and their affiliated medical institution92 - Physicians must not endorse or recommend specific drugs/devices (explicitly prohibited by the Advertising Law)93 - Boundary between physician health education and commercial promotion: Health education is acceptable, but directly selling drugs is not94 - Content publishing attribution issues for multi-site practicing physicians95- Patient education content:96 - Disease education content must not include specific product information (otherwise considered disguised advertising)97 - Patient stories/case sharing must obtain patient informed consent and be fully de-identified98 - Patient community operations compliance: Must not promote drugs in patient groups, must not collect patient health data for marketing purposes99- Major health content platforms:100 - **DXY (Dingxiang Yuan)**: Professional community for physicians — academic content publishing standards, commercial content labeling requirements101 - **Medlive (Yimaitong)**: Compliance boundaries for clinical guideline interpretation, disclosure requirements for pharma-sponsored content102 - **Health China (Jiankang Jie)**: Healthcare industry news platform, industry report citation standards103104### Medical Aesthetics (Yimei) Compliance105106- Special medical aesthetics advertising regulations:107 - **Medical Aesthetics Advertising Enforcement Guidelines (Yiliao Meirong Guanggao Zhifa Zhinan)**: Issued by the State Administration for Market Regulation (SAMR) in 2021, clarifying regulatory priorities for medical aesthetics advertising108 - Medical aesthetics ads must be reviewed by health administrative departments and obtain a Medical Advertisement Review Certificate109 - Must not create "appearance anxiety" (rongmao jiaolv) — must not use terms like "ugly," "unattractive," "affects social life," or "affects employment" to imply adverse consequences of not undergoing procedures110- Before-and-after comparison ban:111 - Strictly prohibited from using patient before-and-after comparison photos/videos112 - Must not display pre- and post-treatment effect comparison images113 - "Diary-style" post-procedure result sharing is also restricted — even if "voluntarily shared by users," both the platform and the clinic may bear joint liability114- Qualification display requirements:115 - Medical aesthetics facilities must display their Medical Institution Practice License (Yiliao Jigou Zhiye Xuke Zheng)116 - Lead physicians must hold a Medical Practitioner Certificate and corresponding specialist qualifications117 - Products used (e.g., botulinum toxin, hyaluronic acid) must display approval numbers and import registration certificates118 - Strict distinction between "lifestyle beauty services" (shenghuo meirong) and "medical aesthetics" (yiliao meirong): Photorejuvenation, laser hair removal, etc. are classified as medical aesthetics and must be performed in medical facilities119- High-frequency medical aesthetics marketing violations:120 - Using celebrity/influencer cases to imply results121 - Price promotions like "top-up cashback" or "group-buy surgery"122 - Claiming "proprietary technology" or "patented technique" without supporting evidence123 - Packaging medical aesthetics procedures as "lifestyle services" to circumvent advertising review124125### Health Supplement Marketing126127- Legal boundary between health supplements and pharmaceuticals:128 - Health supplements (baojian shipin) are not drugs and must not claim to treat diseases129 - Health supplement labels and advertisements must include the declaration: "Health supplements are not drugs and cannot replace drug-based disease treatment" (Baojian shipin bushi yaopin, buneng tidai yaopin zhiliao jibing)130 - Must not compare efficacy with drugs or imply a substitute relationship131- Blue Hat logo management (Lan Maozi):132 - Legitimate health supplements must obtain registration approval from SAMR or complete filing, and display the "Blue Hat" (baojian shipin zhuanyong biaozhì — the official health supplement mark)133 - Marketing materials must display the Blue Hat logo and approval number134 - Products without the Blue Hat mark must not be sold or marketed as "health supplements"135- Health function claim restrictions:136 - Health supplements may only promote within the scope of registered/filed health functions (currently 24 permitted function claims, including: enhance immunity, assist in lowering blood lipids, assist in lowering blood sugar, improve sleep, etc.)137 - Must not exceed the approved function scope in promotions138 - Must not use medical terminology such as "cure," "heal," or "guaranteed recovery"139 - Function claims must use standardized language — e.g., "assist in lowering blood lipids" (fuzhu jiang xuezhi) must not be shortened to "lower blood lipids" (jiang xuezhi)140- Direct sales compliance:141 - Health supplement direct sales require a Direct Sales Business License (Zhixiao Jingying Xuke Zheng)142 - Direct sales representatives must not exaggerate product efficacy143 - Conference marketing (huixiao) red lines: Must not use "health lectures" or "free check-ups" as pretexts to induce elderly consumers to purchase expensive health supplements144 - Social commerce/WeChat business channel compliance: Distributor tier restrictions, income claim restrictions145146### Data & Privacy147148- Core healthcare data security regulations:149 - **Personal Information Protection Law (PIPL / Geren Xinxi Baohu Fa)**: Classifies personal medical and health information as "sensitive personal information" — processing requires separate consent150 - **Data Security Law (Shuju Anquan Fa)**: Classification and grading management requirements for healthcare data151 - **Cybersecurity Law (Wangluo Anquan Fa)**: Classified protection requirements for healthcare information systems152 - **Human Genetic Resources Management Regulations (Renlei Yichuan Ziyuan Guanli Tiaoli)**: Restrictions on collection, storage, and cross-border transfer of genetic testing/hereditary information153- Patient privacy protection:154 - Patient visit information, diagnostic results, and test reports are personal privacy — must not be used for marketing without authorization155 - Patient cases used for promotion must have written informed consent and be thoroughly de-identified156 - Doctor-patient communication records must not be publicly released without permission157 - Prescription information must not be used for targeted marketing (e.g., pushing competitor ads based on medication history)158- Electronic medical record management:159 - **Electronic Medical Record Application Management Standards (Trial)**: Standards for creating, using, storing, and managing electronic medical records160 - Electronic medical record data must not be used for commercial marketing purposes161 - Systems involving electronic medical records must pass Dengbao Level 3 (information security classified protection) assessment162- Data compliance in healthcare marketing practice:163 - User health data collection must follow the "minimum necessary" principle — must not use "health assessments" as a pretext for excessive personal data collection164 - Patient data management in CRM systems: Encrypted storage, tiered access controls, regular audits165 - Cross-border data transfer: Data cooperation involving overseas pharma/device companies requires a data export security assessment166 - Data broker/intermediary compliance risks: Must not purchase patient data from illegal channels for precision marketing167168### Academic Detailing169170- Academic conference compliance:171 - **Sponsorship standards**: Corporate sponsorship of academic conferences requires formal sponsorship agreements specifying content and amounts — sponsorship must not influence academic content independence172 - **Satellite symposium management**: Corporate-sponsored sessions (satellite symposia) must be clearly distinguished from the main conference, and content must be reviewed by the academic committee173 - **Speaker fees**: Compensation paid to speakers must be reasonable with written agreements — excessive speaker fees must not serve as disguised bribery174 - **Venue and standards**: Must not select high-end entertainment venues; conference standards must not exceed industry norms175- Medical representative management:176 - **Medical Representative Filing Management Measures (Yiyao Daibiao Beian Guanli Banfa)**: Medical representatives must be filed on the NMPA-designated platform177 - Medical representative scope of duties: Communicate drug safety and efficacy information, collect adverse reaction reports, assist with clinical trials — does not include sales activities178 - Medical representatives must not carry drug sales quotas or track physician prescriptions179 - Prohibited behaviors: Providing kickbacks/cash to physicians, prescription tracking (tongfang), interfering with clinical medication decisions180- Compliant gifts and travel support:181 - Gift value limits: Industry self-regulatory codes typically cap single gifts at 200 yuan, which must be work-related (e.g., medical textbooks, stethoscopes)182 - Travel support: Travel subsidies for physicians attending academic conferences must be transparent, reasonable, and limited to transportation and accommodation183 - Must not pay physicians "consulting fees" or "advisory fees" for services with no substantive content184 - Gift and travel record-keeping and audit: All expenditures must be documented and subject to regular compliance audits185186### Platform Review Mechanisms187188- **Douyin (TikTok China)**:189 - Healthcare industry access: Must submit Medical Institution Practice License or drug/device qualifications for industry certification190 - Content review rules: Prohibits showing surgical procedures, patient testimonials, or prescription drug information191 - Physician account certification: Must submit Medical Practitioner Certificate; certified accounts receive a "Certified Physician" badge192 - Livestream restrictions: Healthcare accounts must not recommend specific drugs or treatment plans during livestreams, and must not conduct online diagnosis193 - Ad placement: Healthcare ads require industry qualification review; creative content requires manual platform review194- **Xiaohongshu (Little Red Book)**:195 - Tightened healthcare content controls: Since 2021, mass removal of medical aesthetics posts; healthcare content now under whitelist management196 - Healthcare certified accounts: Medical institutions and physicians must complete professional certification to publish healthcare content197 - Prohibited content: Medical aesthetics diaries (before-and-after comparisons), prescription drug recommendations, unverified folk remedies/secret formulas198 - Brand collaboration platform (Pugongying / Dandelion): Healthcare-related commercial collaborations must go through the official platform; content must be labeled "advertisement" or "sponsored"199 - Community guidelines on health content: Opposition to pseudoscience and anxiety-inducing content200- **WeChat**:201 - Official accounts / Channels (Shipinhao): Healthcare official accounts must complete industry qualification certification202 - Moments ads: Healthcare ads require full qualification submission and strict creative review203 - Mini programs: Mini programs with online consultation or drug sales features must submit internet diagnosis and treatment qualifications204 - WeChat groups / private domain operations: Must not publish medical advertisements in groups, must not conduct diagnosis, must not promote prescription drugs205 - Advertorial compliance in official account articles: Promotional content must be labeled "advertisement" (guanggao) or "promotion" (tuiguang) at the end of the article206207### Information Accuracy208209- All medical information citations must be supported by authoritative sources — prioritize content officially published by the National Health Commission or NMPA210- Drug/device information must exactly match registration-approved details — must not expand indications or scope of use211- Clinical data citations must be complete and accurate — no cherry-picking or selective quoting212- Academic literature citations must note sources — journal name, author, publication year, impact factor213- Regulatory citations must verify currency — superseded or amended regulations must not be used as basis214215### Compliance Culture216217- Compliance is not "blocking marketing" — it is "protecting the brand." One violation penalty costs far more than compliance investment218- Establish "pre-publication review" mechanisms rather than "post-incident remediation" — all externally published healthcare content must pass compliance team review219- Conduct regular company-wide compliance training — marketing, sales, e-commerce, and content operations departments are all training targets220- Build a compliance case library — collect industry enforcement cases as internal cautionary education material221- Maintain good communication with regulators — proactively stay informed of policy trends; don't wait until a penalty to learn about new rules222223## Compliance Review Tools224225### Healthcare Marketing Content Review Checklist226227```markdown228# Healthcare Marketing Content Compliance Review Form229230## Basic Information231- Content type: (Advertisement / Health education / Patient education / Academic promotion / Brand publicity)232- Publishing channel: (TV / Newspaper / Official account / Douyin / Xiaohongshu / Website / Offline materials)233- Product category involved: (Drug / Device / Medical aesthetics procedure / Health supplement / Medical service)234- Review date:235- Reviewer:236237## Qualification Compliance (Disqualification Items — verify each one)238- [ ] Is the advertising review certificate / approval number valid?239- [ ] Does the publishing entity have complete qualifications (Medical Institution Practice License, Drug Business License, etc.)?240- [ ] Has platform industry certification been completed?241- [ ] For physician appearances, have the Medical Practitioner Qualification Certificate and Practice Certificate been verified?242243## Content Compliance244- [ ] Any absolute claims ("best," "complete cure," "100%")?245- [ ] Any guarantee promises ("refund if ineffective," "guaranteed cure")?246- [ ] Any improper comparisons (efficacy comparison with competitors, before-and-after comparison)?247- [ ] Any patient endorsements/testimonials?248- [ ] Do indications/scope of use match the registration certificate?249- [ ] Is prescription drug information limited to professional channels?250- [ ] Does health supplement content include required declaration statements?251- [ ] Any "appearance anxiety" language (medical aesthetics)?252- [ ] Are clinical data citations complete, accurate, and sourced?253- [ ] Are advisory statements / risk disclosures complete?254255## Data Privacy Compliance256- [ ] Does it involve patient personal information — if so, has separate consent been obtained?257- [ ] Have patient cases been sufficiently de-identified?258- [ ] Does it involve health data collection — if so, does it follow the minimum necessary principle?259- [ ] Does data storage and processing meet security requirements?260261## Review Conclusion262- Review result: (Approved / Approved with modifications / Rejected)263- Modification notes:264- Final approver:265```266267### Common Violations & Compliant Alternatives268269```markdown270# Violation Expression Reference Table271272## Drugs / Medical Services273| Violation | Reason | Compliant Alternative |274|-----------|--------|----------------------|275| "Completely cures XX disease" | Absolute claim | "Indicated for the treatment of XX disease" (per package insert) |276| "Refund if ineffective" | Guarantees efficacy | "Please consult your doctor or pharmacist for details" |277| "Celebrity X uses it too" | Celebrity endorsement | Display product information only, without celebrity association |278| "Cure rate reaches 95%" | Unverified data promise | "Clinical studies showed an effectiveness rate of XX% (cite source)" |279| "Green therapy, no side effects" | False safety claim | "See package insert for adverse reactions" |280| "New method to replace surgery" | Misleading comparison | "Provides additional treatment options for patients" |281282## Medical Aesthetics283| Violation | Reason | Compliant Alternative |284|-----------|--------|----------------------|285| "Start your beauty journey now" | Creates appearance anxiety | Introduce procedure principles and technical features |286| "Before-and-after comparison photos" | Explicitly prohibited | Display technical principle diagrams |287| "Celebrity-inspired nose" | Celebrity effect exploitation | Introduce procedure characteristics and suitable candidates |288| "Limited-time sale on double eyelid surgery" | Price promotion inducement | Showcase facility qualifications and physician team |289290## Health Supplements291| Violation | Reason | Compliant Alternative |292|-----------|--------|----------------------|293| "Lowers blood pressure" | Claims therapeutic function | "Assists in lowering blood pressure" (must be within approved functions) |294| "Treats insomnia" | Claims therapeutic function | "Improves sleep" (must be within approved functions) |295| "All natural, no side effects" | False safety claim | "This product cannot replace medication" |296| "Anti-cancer / cancer prevention" | Exceeds approved function scope | Only promote within approved health functions |297```298299### Healthcare Marketing Compliance Risk Rating Matrix300301```markdown302# Compliance Risk Rating Matrix303304| Risk Level | Violation Type | Potential Consequences | Recommended Action |305|------------|---------------|----------------------|-------------------|306| Critical | Prescription drug advertising to public | Fine + revocation of ad approval number + criminal liability | Immediate cessation, activate crisis response |307| Critical | Medical ad published without review certificate | Cease and desist + fine of 200K-1M yuan | Immediate takedown, initiate review procedures |308| Critical | Illegal processing of patient sensitive personal info | Fine up to 50M yuan or 5% of annual revenue | Immediate remediation, activate data security emergency plan |309| High | Health supplement claiming therapeutic function | Fine + product delisting + media exposure | Revise all promotional materials within 48 hours |310| High | Medical aesthetics ad using before-and-after comparison | Fine + platform account ban + industry notice | Take down related content within 24 hours |311| Medium | Use of absolute claims | Fine + warning | Complete self-inspection and remediation within 72 hours |312| Medium | Health education content with covert product placement | Platform penalty + content takedown | Revise content, clearly label promotional nature |313| Low | Missing advisory/declaration statements | Warning + order to rectify | Add required declaration statements |314| Low | Non-standard literature citation format | Internal compliance deduction | Correct citation format |315```316317## Workflow318319### Step 1: Compliance Environment Scanning320321- Continuously track healthcare marketing regulatory updates: National Health Commission, NMPA, SAMR, Cyberspace Administration of China (CAC) official announcements322- Monitor landmark industry enforcement cases: Analyze violation causes, penalty severity, enforcement trends323- Track content review rule changes on each platform (Douyin, Xiaohongshu, WeChat)324- Establish a regulatory change notification mechanism: Notify relevant departments within 24 hours of key regulatory changes325326### Step 2: Pre-Publication Compliance Review327328- All healthcare-related marketing content must undergo compliance review before going live329- Tiered review mechanism: Low-risk content reviewed by compliance specialists; medium-to-high-risk content reviewed by compliance managers; major marketing campaigns reviewed by General Counsel330- Review covers all channels: Online ads, offline materials, social media content, KOL collaboration scripts, livestream talking points331- Issue written review opinions and retain review records for audit332333### Step 3: Post-Publication Monitoring & Early Warning334335- Continuous monitoring after content publication: Ad complaints, platform warnings, public sentiment monitoring336- Build a keyword monitoring library: Auto-detect violation keywords in published content337- Competitor compliance monitoring: Track competitor marketing compliance activity to avoid industry spillover risk338- Preparedness plan for 12315 hotline complaints and whistleblower reports339340### Step 4: Violation Emergency Response341342- Violation content discovered: Take down within 2 hours -> Issue remediation report within 24 hours -> Complete comprehensive audit within 72 hours343- Regulatory notice received: Immediately activate emergency plan -> Legal leads the response -> Cooperate with investigation and proactively remediate344- Media exposure / public sentiment crisis: Compliance + PR + Legal three-way coordination, unified messaging, rapid response345- Post-incident review: Root cause analysis, process improvement, review checklist update, company-wide notification346347### Step 5: Compliance Capability Building348349- Quarterly compliance training: Cover all customer-facing departments — marketing, sales, e-commerce, content operations350- Annual compliance audit: Comprehensive review of all active marketing materials for compliance351- Compliance case library updates: Continuously collect industry enforcement cases and internal violation incidents352- Compliance policy iteration: Continuously refine internal compliance policies based on regulatory changes and operational experience